JAK抑制剂阻断T细胞诱导的促炎性巨噬细胞活化
研究从健康供者外周血分离CD14+单核细胞与CD4+ T细胞,在Tck细胞分化过程中加入托法替布或鲁索替尼,再用ELISA检测Tck细胞活化巨噬细胞产生的细胞因子与趋化因子。结果显示JAK抑制剂阻止细胞因子诱导的Tck细胞成熟,并降低TNF、IL-6、IL-15、IL-1RA及IL-10、MIP1α、MIP1β、IP10的产生(p<0.05)。作者认为抑制T细胞-巨噬细胞相互作用可能参与JAK抑制剂的治疗效应。
要点
- 托法替布或鲁索替尼在体外阻止细胞因子诱导的Tck细胞成熟。
- JAK抑制剂降低Tck细胞活化巨噬细胞产生的TNF、IL-6、IL-15、IL-1RA(p<0.05)。
- JAK抑制剂降低Tck细胞活化巨噬细胞产生的IL-10、MIP1α、MIP1β、IP10(p<0.05)。
核心结论
- JAK抑制阻断T细胞诱导的巨噬细胞活化,并减少下游促炎细胞因子和趋化因子反应。
- 作者认为抑制T细胞-巨噬细胞相互作用可能有助于JAK抑制剂的治疗效应。
研究设计与样本
- 体外研究:从健康供者血沉棕黄层的外周血单核细胞中纯化CD14+单核细胞和CD4+ T细胞。
- 在Tck细胞分化过程中加入托法替布或鲁索替尼作为代表性JAK抑制剂。
- 采用既往验证的方案分别从单核细胞和CD4+ T细胞生成巨噬细胞和Tck细胞,用ELISA检测细胞因子和趋化因子。
主要发现
- JAK抑制剂阻止细胞因子诱导的Tck细胞成熟。
- JAK抑制剂降低Tck细胞活化巨噬细胞产生的促炎细胞因子TNF、IL-6、IL-15、IL-1RA(p<0.05)。
- JAK抑制剂降低Tck细胞活化巨噬细胞产生的趋化因子IL-10、MIP1α、MIP1β、IP10(p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Macrophage subsets, activated by T cells, are increasingly recognised to play a central role in rheumatoid arthritis (RA) pathogenesis. Janus kinase (JAK) inhibitors have proven beneficial clinical effects in RA. In this study, we investigated the effect of JAK inhibitors on the generation of cytokine-activated T (Tck) cells and the production of cytokines and chemokines induced by Tck cell/macrophage interactions. METHODS: CD14+ monocytes and CD4+ T cells were purified from peripheral blood mononuclear cells from buffy coats of healthy donors. As representative JAK inhibitors, tofacitinib or ruxolitinib were added during Tck cell differentiation. Previously validated protocols were used to generate macrophages and Tck cells from monocytes and CD4+ T cells, respectively. Cytokine and chemokine including TNF, IL-6, IL-15, IL-RA, IL-10, MIP1α, MIP1β and IP10 were measured by ELISA. RESULTS: JAK inhibitors prevented cytokine-induced maturation of Tck cells and decreased the production of proinflammatory cytokines TNF, IL-6, IL-15, IL-1RA and the chemokines IL-10, MIP1α, MIP1β, IP10 by Tck cell-activated macrophages in vitro (p<0.05). CONCLUSIONS: Our findings show that JAK inhibition disrupts T cell-induced macrophage activation and reduces downstream proinflammatory cytokine and chemokine responses, suggesting that suppressing the T cell-macrophage interaction contributes to the therapeutic effect of JAK inhibitors.
引用
- Nyirenda MH, Nijjar JS, Frleta-Gilchrist M, et al. JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation. RMD Open. 2023. PMID: 36599629. doi:10.1136/rmdopen-2022-002671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。